Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement

Ibnu Purwanto¹, Iwan Dwiprahasto², Teguh Aryandono³, Sofia Mubarika⁴

¹Division of Hematology and Medical Oncology, Department of Internal Medicine, ²Department of Pharmacology and Therapy, ³Division of Surgical Oncology, Department of Surgery, ⁴Department of Histology and Cell Biology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia

ABSTRACT

Triple negative breast cancer (TNBC) is still associated with grave prognosis, especially compared to other breast cancer subtypes. Advances in medical science have improved our understanding on the biological nature and heterogeneity of TNBC, explaining the efficacy variability of existing chemotherapeutic drugs on TNBC patients. Complexity of TNBC has led to wide variation of TNBC treatment across the globe, resulting in unsatisfactory treatment outcome. This issue is further complicated by the absence of TNBC treatment guideline in many countries, including in Indonesia. This review discusses systemic treatment options for TNBC while taking account its molecular heterogeneity. Specific consideration is made for Indonesia, not only for current clinical practice, but also for future improvements. Immunotherapy, especially programmed cell death 1 (PD-1/PD-L1) inhibitor, has recently shown promising result in TNBC patients. It can be concluded that TNBC is heterogenous and treatment option should be tailored based on its molecular profile.

Keywords: triple negative; breast cancer; Indonesia; treatment; immunotherapy

*corresponding author: dribnupwt@yahoo.com
INTRODUCTION

Triple negative breast cancer (TNBC) accounts for 10 – 20% of all breast cancers which roughly translates into 200,000 of new cases annually worldwide.\(^1\,2\) Epidemiological data of Indonesian showed that TNBC patients is very rare. According to reports from Widodo et al.\(^3\) and Sitohang et al.,\(^4\) TNBC accounts for 20-25% of all breast cancer cases in Dr. Sardjito General Hospital, Yogyakarta, Indonesia. TNBC is a very heterogeneous disease with wide variety of genetic expression and mutations. Collectively TNBC has the worst survival compared to other breast cancer subtypes. Existing treatment modalities still do not result in acceptable survival outcome.\(^5\) Although both ESMO and ASCO (NCCN) have published treatment guidelines for TNBC, there is still no standard chemotherapy regimen for TNBC, leading to wide variation of TNBC treatment across the globe.\(^6\,8\)

In Indonesia, TNBC patients are mainly treated surgically followed by adjuvant chemotherapy. Since currently there is no guideline for TNBC treatment in Indonesia, Indonesian health professionals have to adapt and implement multiple international guidelines into their daily practice, albeit with limited success. The lack of consensus on choosing chemotherapy regimen for TNBC patients in Indonesia further complicates this issue. The aimed of this review paper was to provide recommendation and suggestion for the development of Indonesian guideline on TNBC treatment as well as for other developing countries that donot have such guideline at the moment.

LITERATURE REVIEW

TNBC heterogeneity

TNBC is immunohistochemically defined as the lack of estrogen receptor (ER) and progesterone receptor (PR) expression accompanied with the lack of human epidermal growth FACTOR receptor2 (HER2) overexpression.\(^9\) According to American society of clinical oncology/college of American pathologist (ASCO/CAP) guidelines, ER and PR expression have to be ≤ 1% for them to be considered as negative.\(^10\) Classifying TNBC according to IHC is not enough as the heterogeneity of TNBC extend beyond ER, PR, and HER2 expression alone. Multiple attempts have been done to improve the classification of TNBC with the most widely discussed at the moment being classification by Perou et al.\(^11\) (PAM50) and Lehmann et al.\(^12\) (Vanderbilt).\(^12\,16\)

Perou et al.\(^11\) provided the first insight on “intrinsic subtypes” of breast cancer based on gene expression profiling analysis. Perou et al.\(^11\) came up with 4 intrinsic subtypes of breast cancer, namely luminal, HER2-enriched, basal-like and normal breast-like. Breast cancer subtypes according to Perou’s classification was further added by research done by Sørlie et al.\(^12\) which divided luminal subtypes into luminal A and B. Prat et al.\(^17\) added Claudin Low subtype. Throughout the years, this classification has been intensively studied and has showed clinical and prognostic significance, albeit limited.\(^12\,15\) Prat et al.\(^14\) later refined the 6 subtypes classification into 2 subtypes, basal-like and non-basal-like.

Lehmann et al.\(^18\) initially classified TNBC into 6 subtypes (also known as TNBC type), namely basal-like 1 and 2 (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem–like (MSL), and luminal androgen receptor (LAR). Further research then considered IM and MSL subtypes to had been defined by the high expression of genes from the tumor microenvironment and not from the actual tumor cells, leading to the omission of IM and MSL subtypes from the refined classification,
also known as TNBCtype-4.\textsuperscript{14,16} Masuda \textit{et al.}\textsuperscript{19} investigated the clinical relevance of the original Vanderbilt classification (TNBCtype) in neoadjuvant setting with anthracycline and taxane chemotherapy. They found that BL1 subtype had the highest pathologic complete response (pCR) rate (52%) and BL2 and LAR had the lowest (0 and 10%, respectively).

Although Perou \textit{et al.}\textsuperscript{11} (later refined by Prat \textit{et al.}\textsuperscript{14}) and Lehmann \textit{et al.}\textsuperscript{16} came up with different classifications, both shared some overlapping entities. Both classifications came up with 3 basic subtypes, mesenchymal, basal-like, and LAR in Vanderbilt classification and Claudin-low, basal-like and luminal/HER2E in PAM50 classification.\textsuperscript{14} Apart from significant scientific contribution, neither of the two classifications can fully describe the heterogeneity of TNBC's biological characteristic which causes more researchers to try to find a better classification of TNBC. Burstein \textit{et al.}\textsuperscript{20} thought gene profiling alone might not be enough to classify TNBC and attempted to combine gene profiling with transcriptomic analysis according to mRNA to classify TNBC (Baylor classification). Burstein \textit{et al.}\textsuperscript{20} classified TNBC into 4 subtypes, namely: luminal-AR (LAR), mesenchymal (MES), basal-like immune-suppressed (BLIS), and basal-like immune-activated (BLIA). Out of the four subtypes, BLIS subtype has the best prognosis for both DFS and DSS while BLIA has the worst. According to Burstein \textit{et al.}\textsuperscript{20} Baylor classification does have some similarities with both Vanderbilt and PAM50 classifications. The LAR subtype in Baylor classification is very similar with LAR subtype in Vanderbilt classification while both BLIS and BLIA subtypes from Baylor classification are entirely classified as basal-like according to PAM50 classification.\textsuperscript{20}

Current classifications of TNBC allow researchers to systematically analyze treatment effect on different TNBC subtypes. Although useful in clinical trials, more evidence is needed to establish the prognostic and therapeutic value of these classifications.

**TNBC in Asian population**

Race and ethnic group are known to influence characteristic and prognosis of TNBC.\textsuperscript{21} Compared to America, India has higher prevalence of TNBC (>30% of all breast cancer) and is associated with younger age at diagnosis and worse prognosis.\textsuperscript{22-25} Different pattern is observed in Chinese population. China has one of the lowest prevalence of TNBC among Asian countries (around 10.4-13.5% of all breast cancer) with significantly better survival compared to other population (5- and 10-year OS were as high as 79.92 and 82%, respectively).\textsuperscript{26,27} Currently, there is no data of TNBC survival in Indonesian patients, although the incidence is around 20-25% of all breast cancer cases, relatively high compared to other countries.\textsuperscript{3,4}

**TNBC treatment modalities**

**Local control**

Surgery and radiotherapy in TNBC are principally similar with other breast cancer subtypes and will not be discussed in this paper.

**Systemic therapy**

Systemic chemotherapy, both as adjuvant and neoadjuvant therapy, is the main treatment of TNBC. All of the chemotherapy regimens used in breast cancer in general can be used in TNBC with anthracycline- and taxane-based chemotherapy being the more preferred option for both adjuvant and neoadjuvant settings.\textsuperscript{28-30}

**Platinum salt**

Addition of platinum salt towards standard chemotherapy regimen had
been proven to improve survival in TNBC patients. CALGB 40603 trial showed that addition of carboplatin to standard regimen (paclitaxel 80 mg/m² once a week for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles) significantly increased pCR breast (60% vs. 44%; p=0.0018) and pCR breast/axilla (54% vs. 41%; p=0.0029).\textsuperscript{31} Follow-up analysis of CALGB 40603 trial reported that three-year overall EFS was 74.1% and OS 83.2%. Patients who achieved pCR breast had significantly better three-year EFS compared to those who did not (84.8% vs. 61.8%).\textsuperscript{32} Although it should be noted that the addition of carboplatin or bevacizumab significantly increased chemotherapy-related toxicity which decreased the chance for patients to complete the standard chemotherapy regimen without skipped doses, dose modification, or early discontinuation.

Similar with CALGB 40603 trial, GeparSixto trial also showed that the addition of carboplatin to standard regimen (18 weeks of paclitaxel 80 mg/m² once a week and non-pegylated liposomal doxorubicin 20 mg/m² once a week) increased pCR rate in TNBC patients (53.2% vs. 58%; p=0.005) but not in HER2-positive breast cancer. Increased incidence of chemotherapy associated toxicity due to the addition of carboplatin also observed in GeparSixto trial.\textsuperscript{33} Comparing 2 of the most commonly used platinum agents in treating metastatic TNBC patients, phase II TBCR009 trial found that cisplatin had a better response rate compared to carboplatin (32.6% vs. 18.7%). The overall response rate for both agents combined was 25.6% and was particularly high in individuals with BRCA1/2 mutations compared to the ones without the mutation (54.5% vs. 19.7%).\textsuperscript{34} Long term follow-up showed that stage II/III TNBC patients treated with paclitaxel (175 mg/m², day1) plus carboplatin (area under the curve = 5, day2) resulted in significantly higher five-year recurrence-free survival (RFS) compared to patients treated with epirubicin (75mg/m², day1) plus paclitaxel (175mg/m², day2) (EP) (77.6% vs. 56.2%; p=0.014). Five-year OS were not significantly different between 2 treatment arms (83.3% vs. 70.7%; p=0.350). Patients who achieved pCR had significantly better five-year RFS (94.7% vs. 56.1%; p=0.043) and OS (100.0% vs. 67.2%; p=0.004).\textsuperscript{35}

The effectiveness of platinum salt in treating TNBC is thought to be caused by formation of DNA-platinum adducts which leads to inter- and intra-strand cross-links. This cross-linking of DNA interferes with replication and transcription which results in the breaking of a double-stranded DNA strand and ultimately results in cell death.\textsuperscript{36} Platinum is especially effective in TNBC with BRCA1 germline mutation because BRCA1 is a mediator of homologous recombination (HR) and mutation of BRCA1 leads to decreased DNA repair and DNA stability. Byrski \textit{et al.}\textsuperscript{37} observed 90% pCR rate in 10 patients with BRCA1 mutation (9 TNBC, 1 incomplete data) treated with cisplatin (75mg/m² every 3weeks for four cycles). Effectiveness of platinum in BRCA mutated patients is further elucidated in another study by Byrski \textit{et al.}\textsuperscript{37} In this study 102 BRCA1 mutation carriers were treated with different chemotherapy regimens and the highest pCR rate was achieved in patients treated with cisplatin (83%), followed by AC/FAC regimen (22%), AT regimen (8%), and CMF regimen (7%). Although positive results have been seen in BRCA1 mutated TNBC patients, BRCA1 mutation is found only in 23-57% of all TNBC cases.\textsuperscript{38,39} Incidence of BRCA mutation seems to be varied according to race and country.\textsuperscript{40} Nanda \textit{et al.}\textsuperscript{41} observed that BRCA mutations were highest among Ashkenazi Jewish families, followed by Caucasians and African Americans (69.0, 46.2, and 27.9% respectively). In Indonesia, studies have shown that BRCA mutations
occurred in 0-7.8% of all breast cancer patients,\(^{42,43}\) which is similar with other Asian countries.\(^{44,45}\) Furthermore, BRCA1 mutation represent only a fraction of basal-like subtype according to PAM50 or BL1 and BL2 according to Vanderbilt classification which means there is still a huge proportion of TNBC patients that requires different treatment approach.\(^{14,18}\)

**PARP inhibitor**

Poly (ADP-ribose) polymerase (PARP) is important in facilitating base excision repair (BER).\(^{46}\) As BER is essential in single-strand DNA breaks repair, inhibition of PARP may lead to accumulation of DNA single-strand breaks, which in the absence of double-strand homologous recombinant (HR) repair mechanism, causes “synthetic lethality”.\(^{47}\) In many breast cancer cases, including TNBC, double-strand HR repair defect is associated with BRCA1 mutation.\(^{38,39,48}\) Since PARP is highly expressed in more than 80% of BRCA1 mutated TNBC patients, inhibition of PARP is thought to add benefit in treatment of TNBC.\(^{49,50}\)

The positive impact of PARP inhibitor in the treatment of TNBC patients was shown in a phase II trial by O'Shaughnessy et al.\(^{51}\) This study found that the addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34 to 56% (p=0.01) and the rate of overall response from 32 to 52% (p=0.02). The median progression-free survival (PFS) and overall survival (OS) were also prolonged with the addition of iniparib (3.6 vs. 5.9 months and 7.7 vs. 12.3 months respectively). However, the positive result from phase II trial did not translate very well in the phase III confirmation trial as the addition of iniparib to gemcitabine and carboplatin showed that improved OS (HR 0.65; 95%CI: 0.46-0.91) and PFS (HR 0.68; 95%CI: 0.50-0.92) only seen when the regimen was given as second-/third-line treatment.\(^{52}\)

Other types of PARP inhibitor have been tested in clinical trials and showed positive result in treating TNBC. A report published from I-SPY 2 trial showed that addition of carboplatin and veliparib to standard chemotherapy regimen [12 cycles of weekly paclitaxel followed by doxorubicin/cyclophosphamide (AC) X 4] increased pCR rate of TNBC patients (51% vs. 26%) with 88% predicted probability of phase 3 success.\(^{53}\) A phase III trial of 302 patients by Robson et al.\(^{54}\) found that olaparib (PARP1 and PARP2 inhibitor) improves the outcome of metastatic breast cancer patients with BRCA mutation. Median progression-free survival was significantly longer in the olaparib group compared to the standard-therapy group (7.0 vs. 4.2 months; PFS: HR 0.58, 95%CI: 0.43-0.80). The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group with sub analysis result showing significantly better response in TNBC patients compared to hormone-receptor positive patients/HR 0.43 (95%CI: 0.29-0.63) vs 0.82 (95%CI: 0.55-1.26).\(^{54}\)

**EGFR inhibitor**

Epidermal growth factor receptor (EGFR), a member of ErbB family of receptor tyrosine kinases has been showed to be important contributor of tumor cell proliferation, migration, and survival.\(^{55-58}\) Research has showed that EGFR expression tend to be higher in TNBC patients when compared to non-TNBC patients, is more frequently seen in basal subtype and associated with worse prognosis.\(^{14,18,59-61}\) However, reports on the frequency of EGFR overexpression in TNBC have been varied (13-89%), with lower frequency particularly observed in Korean patients (13-30%), suggesting EGFR overexpression might be influenced by race.\(^{60,62,63}\) As EGFR is involved in various carcinogenesis processes and is highly expressed in TNBC, the addition
of EGFR inhibitor theoretically will add benefit in TNBC patients. Despite promising results in preclinical studies, results from clinical trials have been lackluster at best. Most trials reported that the addition of EGFR inhibitor didn’t result in significant clinical response in advanced TNBC patients and was associated with increased incidence of chemotherapy-related side effects, especially hematological toxicities.\textsuperscript{64-67} The only clinically significant result of EGFR inhibitor so far was reported by Carey \textit{et al.}\textsuperscript{68} with 6% response rate (RR) shown in the addition of cetuximab in metastatic TNBC treatment, while cetuximab plus carboplatin resulted in 16% RR after progression. Disappointing results from clinical trials makes it difficult to suggest the usage of EGFR inhibitor in TNBC treatment. However, because further research on this topic is ongoing, the role of EGFR inhibitor in management of TNBC patients has not been determined.

\textbf{Androgen receptor inhibitor}

Androgen receptor (AR) is expressed in all of breast cancer subtypes, including TNBC.\textsuperscript{69-72} Research has shown that AR is expressed in 12-53% of all TNBC patients.\textsuperscript{72-75} The wide frequency difference of AR expression between studies is partly explained by the absence of standardized method of determining AR positivity. AR negativity in TNBC is associated with younger age at diagnosis and worse prognosis in African American women. Classification of TNBC by Lehmann \textit{et al.}\textsuperscript{16} and Burstein \textit{et al.}\textsuperscript{20} grouped AR expressing TNBC as a separate entity (LAR subtype). This LAR subtype was observed to have lower rate of response towards neo-adjuvant chemotherapy, suggesting the need for different treatment approach towards this subtype.\textsuperscript{19}

Due to the success of targeting estrogen and progesterone receptors in treating hormone positive breast cancer, research on the effectiveness of AR inhibitor in treating breast cancer, especially TNBC became more prevalent. As a proof of concept for the role of AR inhibitor in treating TNBC, Gucalp \textit{et al.}\textsuperscript{75} reported that bicalutamide showed 19% clinical benefit rate (CBR) when given to ER-PR- metastatic breast cancer patients. Similar with previous study, Bonnefoi \textit{et al.}\textsuperscript{76} reported that the addition of abiraterone acetate (AA) and prednisone resulted in 20% CBR and 6.7% objective response rate (ORR) in advanced AR+ TNBC patients. More recently, a phase II study by Traina \textit{et al.}\textsuperscript{77} reported that enzalutamide resulted in 33.3% of CBR when given to AR+ TNBC patients treated with 0-1 prior lines of therapy with fatigue as the only grade 3 or higher drug related toxicity.

\textbf{PD-1/PD-L1 inhibitor}

Programmed death 1 receptor (PD-1) is an immune checkpoint receptor and when bound to its PD-L1 ligand, results in immunoinhibitory response which contributes to cancer cell survival and progression.\textsuperscript{78-81} In cases of cancer that expresses PD-1/PD-L1, inhibition of PD-1/ PD-L1 results in cancer cell death. Studies have shown that PD-1/PD-L1 expression in TNBC tend to be higher when compared to non-TNBC with estimated frequency of 20-58% in all of TNBC patients.\textsuperscript{82-86}
High expression of PD-1/PD-L1 has been associated with high expression of TILs, including in TNBC. Higher expression of TILs is associated with better survival in TNBC patients, suggesting the potential of PD-1/PD-L1 inhibitor as a candidate for TNBC treatment.

Promising results have been seen in clinical studies of PD-1/PD-L1 inhibitor in TNBC treatment. A phase 1b KEYNOTE-012 study by Nanda et al. reported that single agent pembrolizumab (10 mg/kg every 2 weeks) treatment in advanced TNBC patients resulted in 18.5% ORR accompanied by generally mild drug-related toxicity, although 15.6% of the patients experienced grade ≥ 3 toxicity and one patient died due to treatment-related cause. In phase II study, Nanda et al. reported that the addition of pembrolizumab increased the raw pCR rate by 52.1% (19.3 to 71.4%) and estimated pCR rate by > 40%, with predicted probability of success in phase III trial of 99.3%. Immune-related toxicities were observed in 5 of 69 patients included in this study, which were hypophysitis (1 patient) and adrenal insufficiency (4 patients). Given as first line therapy in metastatic TNBC patients, pembrolizumab (200 mg Q3W) monotherapy showed 23% ORR with manageable safety profile.

Other trials have also showed similarly positive results of PD-1/PD-L1 inhibitor in advanced TNBC patients. A phase 1b KEYNOTE-173 study by Schmid et al. reported overall ORR (CR+PR) before surgery of 80% (90% CI: 49-96) in A (single-dose pembrolizumab followed by 4 cycles of pembrolizumab Q3W + nab-paclitaxel (Np) weekly followed by 4 cycles of pembro + doxorubicin + cyclophosphamide Q3W) and 100% (90% CI: 74-100) in B (same as in A but with carboplatin Q3W added to pembro + Np). ypT0/Tis pCR rate was 70% (90% CI: 39-91) in A and 100% (90% CI: 74-100) in B; ypT0 ypN0 pCR rate was 50% (90% CI: 22-78) in A and 90% (90% CI: 61-100) in B; and ypT0/Tis ypN0 pCR rate was 60% (90% CI: 30-85) in A and 90% (90% CI: 61-100) in B. A phase Ib trial by Adams et al. showed that atezolizumab (800 mg Q2W; d1,15) and nab-paclitaxel (125 mg/m² Q1W; d1,8,15, q3 of 4 weeks) resulted in 42% confirmed ORR. PD-1/PD-L1 inhibitor is perhaps the most promising immunotherapy agent for TNBC that we have so far, although more evidence is still needed to support routine use of this agent for TNBC treatment.

**Eribulin**

Eribulin, a microtubule inhibitor, recently has shown positive results when given to TNBC patients. A phase III clinical trial assessing the effect of eribulin on pretreated metastatic breast cancer showed that the addition of eribulinmesylate 1.4 mg/m² significantly improved PFS (HR 0.77; 95% CI: 0.60-0.97; p=0.028) and OS (HR 0.72; 95% CI: 0.57-0.90; p=0.005) in TNBC patients. In another study, Manikhas et al. observed that metastatic TNBC patients treated with erbulin resulted in 9.6% of clinical ORR and 46.1% stable disease with relatively well-tolerated drug-related toxicity. More recently, a phase Ib/II trial showed that eribulin in combination with pembrolizumab resulted in ORR of 29.2% (95% CI: 18.6-41.8) when given to metastatic TNBC patients (Eisai Co Ltd, 2017).
### TABLE 1. Summary of considerations in choosing treatment options

| Treatment option                  | Consideration                                                                                                                                 |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Anthracyline + taxane chemotherapy| Generally, is the regimen of choice for initial treatment, both in neoadjuvant and adjuvant setting.                                           |
| Platinum salt                    | Generally sensitive for TNBC, is associated with the best outcome compared to other systemic chemotherapy regimen, especially in BRCA1(+). Can be used as 1st line agent. |
| PARP inhibitor                   | Improves survival when given in combination with platinum-based chemotherapy, possibly through “synthetic lethality.”                         |
| EGFR inhibitor                   | Theoretically will add benefit in TNBC patient. Phase II studies have shown small but significant clinical response. Currently evidence is still lacking to support routine use of this agent to treat TNBC. |
| AR inhibitor                     | Androgen receptor is known to be expressed in some TNBC patients. Phase II studies have shown moderate clinical response. More evidence is required to understand its role in TNBC treatment. |
| PD-1/PDL-1 inhibitor             | Promising agent for TNBC treatment. Multiple phase II studies have shown positive result in metastatic setting when used in combination with other chemotherapy agents. |
| Eribulin                         | Moderate response is observed when given to metastatic patients. Although its role in improving survival, especially in early stage TNBC, is unknown. |

**TP53 inhibitor**

TP53, a tumor suppressor gene, is one of the most frequently found mutated gene in TNBC (64-82%) and is often associated with worse response to treatment and survival. TP53 has been hypothesized as one of the most important driving forces in carcinogenesis of TNBC, suggesting its potential as a therapeutic target. Preclinical studies have shown positive effect of TP53 inhibition in TNBC cell lines, albeit have not been validated by clinical trials. Currently, two anti-TP53 drugs, APR-246 and COTI-2 are undergoing phase I clinical trials on other types of cancer that show high rate of TP53 mutation, showing tolerable toxicity, and promising efficacy.

**MiRNA inhibitor**

Inhibition of miRNA has been discussed as an option to treat TNBC as it is known that certain types of miRNA are associated with the survival of TNBC patients. Meta-analysis by Lü et al. showed that decreased expression of miR-155 and increased expression of miR-21 were predictive of reduced OS. Lü et al. also found that elevated levels of miR-27a/b, miR-210, and miR-454 expression were associated with shorter OS, while the levels of miR-454 and miR-374a/b expression were associated with DFS. A study by Svoboda et al. observed that miR-34b expression negatively correlated with DFS and OS in TNBC patients. Research on the therapeutic role of miRNA for TNBC is currently in preclinical phase. Li et al. reported that miR-454 promoted and enhanced the proliferation, migration and invasion of TNBC cells. Overexpression of miR-454 inhibited TNBC cell death by ionizing radiation through the regulation of caspase 3/7 and Bcl-2 expression. Chen et al. observed that miR-211-5p was significantly down regulated in TNBC and its expression level was associated with overall survival in TNBC. The expression of miR-211-5p suppressed TNBC cell proliferation, invasion, migration and metastasis in vitro and in vivo. Although there is no
targeted therapy aimed specifically at certain miRNA, recent reports have shown that the serum level of various miRNA is affected by chemotherapy and might be associated with patient survival, suggesting their involvement in healing process. There is substantial amount of miRNA which are potential targets for future TNBC therapy. Unfortunately, we have not reached adequate understanding on the best way to target miRNA to treat TNBC, thus significant progress from preclinical studies is needed before we can move on to clinical trials.

**PI3K/AKT/mTOR inhibitor**

Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) is one of the most important pathways in cell survival, proliferation, and metastasis of certain cancers. During the creation of their classification, Lehmann et al. observed that multiple components of PI3K/AKT/mTOR pathway were mutated in some TNBC patients, especially the ones classified into mesenchymal-like and mesenchymal stem-like subtypes. In recent years many discussions had taken place discussing whether inhibition of PI3K/AKT/mTOR pathway would lead to better survival in TNBC patients. Preclinical studies have shown that multiple agents targeting various points in PI3K/AKT/mTOR pathway have resulted in growth arrest of TNBC cell lines. At the moment, there are numerous trials underway assessing PI3K/AKT/mTOR inhibitors in TNBC patients. Using metaplastic TNBC as a surrogate for mesenchymal TNBC, apha I trial showed that the combination of liposomal doxorubicin, bevacizumab, and temsirolimus or everolimus resulted in 21% ORR (8% CR, 13% PR) and 19% stable disease for at least 6 months, for a clinical benefit rate of 40%. The presence of PI3K pathway aberration was associated with a significant improvement in ORR (31 vs. 0%; p=0.04) but not CBR (44 vs. 45%; p > 0.99). Although not yet proven to be efficacious as monotherapy, PI3K/AKT/mTOR inhibitors might be useful as combination therapy in metastatic TNBC patients. Reports from ongoing phase II studies will improve our understanding on the best way to utilize these drugs in treating TNBC.

**DISCUSSION**

Studies from the past two decades have revealed the complexity and heterogeneity of TNBC. Expression and mutation of various genes are known to have prognostic value and cause different response towards chemotherapy, explaining the disparity of survival between race and ethnic groups in TNBC. This issue is especially problematic for a country such as Indonesia, which population is not only numerous (4th most numerous in the world), but also heterogenous (comprised of more than 730 ethnic groups). According to genetic pattern and anthropological analysis, Indonesian population has ancestral lineage stemming from China, India, and Africa, resulting in genetically unique and diverse population. Potential solution for this problem is by implementation of targeted therapy which would allow for a more personalized medicine. Unfortunately, targeted therapy in Indonesia is still very expensive and not covered by Indonesian National Insurance, thus chemotherapy is still the more suitable approach at the moment.

TNBC is associated with higher sensitivity towards chemotherapy treatment compared to other subtypes, albeit is also associated with higher rate of recurrence and distant metastasis. Liedtke et al. observed that TNBC patients who received NAC treatment achieved higher rate of pCR when compared to non-TNBC patients.
(22 vs. 11%; p = 0.034) but had decreased three-year progression-free survival rates (p = 0.0001) and three-year overall survival (OS) rates (p = 0.0001). However, similar survival is observed between non-TNBC patients and TNBC patients if pCR is achieved. The association between pCR status and improved survival was later confirmed by Cortazar et al. performed meta-analysis and found that TNBC patients had the strongest association between pCR and event-free survival (EFS) (HR 0.39, 95% CI: 0.31-0.50) with the weakest association shown in HER2-positive, hormone positive subtype (HR 0.58, 95% CI: 0.42-0.82). Although all of the chemotherapy regimens used in treating breast cancer in general can be used in treating TNBC, platinum-based regimen is observed to be the best regimen for TNBC patients in Indonesia, especially for patients expressing BRCA mutation.

Targeted immunotherapy such as PD-1/PD-L1 inhibitor has proven to be useful in TNBC patients, both given as single agent, as well as in combination with chemotherapy. The effectiveness of PD-1/PD-L1 inhibitor has resulted in increased research interest in finding more immune checkpoints as potential target for therapy in TNBC, including CD73 and CDCP1.

**CONCLUSION**

Heterogeneity of TNBC makes it impossible for the development of “one for all” treatment. Response towards existing treatment modalities has been diverse across all TNBC subtypes. Although, there is not a single target molecule which is highly expressed in all of TNBC patients, targeted therapy, especially PD-1/PD-L1 inhibitor, has shown promising results but still require further validation through phase III and IV clinical trials.

Reports have shown that race and genetic profile are important risk factors and prognostic factors of TNBC. While research in Europe, East Asia and USA is numerous, TNBC research in Southeast Asia, especially in Indonesia is still far from adequate thus limiting our knowledge on how applicable research results from other countries to highly heterogeneous Indonesian patients. Before breakthrough in clinical research can be made, it is imperative for Indonesia to strengthen its epidemiological and molecular data. An ongoing collaboration between International Agency for Research on Cancer (IARC) and Dr. Sardjito General Hospital, Yogyakarta for the development of population-based cancer registry (PBCR) serves as an important stepping stone to reach that goal. It is also important for Indonesia to improve its efficiency on conducting clinical research. Instead of conducting multiple conventional trials assessing 1 treatment regimen at a time, implementation of centrally coordinated research through a platform similar to the one used in I-SPY 2 trial can substantially increase clinical research output as it allows for assessment of multiple treatment regimens at the same time. Further improvement on research efficiency can be done by shifting from adjuvant to neoadjuvant chemotherapy as pCR has been proven by other studies as a predictor that can be done for long-term survival in TNBC.

**ACKNOWLEDGEMENTS**

We would like to thanks to all those who gave their hands and supports so that we able to complete this article review.

**REFERENCES**

1. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian
patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110(4):876-84. https://doi.org/10.1002/cncr.22836

2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109(9):1721-8. https://doi.org/10.1002/cncr.22618

3. Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathological features of indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev 2014; 15(15):6109-13. https://doi.org/10.7314/apjcp.2014.15.15.6109

4. Sitohang F, Kurnianda J, Ghozali A, Widayati K, Purwanto I. Clinicopathological features and KI67 proliferation index in patients with non-metastatic triple negative breast cancer in Yogyakarta. China:20th CSCO Annual Meeting; Xiamen. 2017.

5. Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008; 44(18):2799-805. https://doi.org/10.1016/j.ejca.2008.09.034

6. Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013; 24(5):1219-25. https://doi.org/10.1093/annonc/mds603

7. Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 2015; 136(1):204-11. https://doi.org/10.1002/ijc.28966

8. Staudacher L, Cottu PH, Diéras V, Vincent-Salomon A, Guilhaume MN, Escalup L, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22(4):848-56. https://doi.org/10.1093/annonc/mdq461

9. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7(12):683-92. https://doi.org/10.1038/nrclinonc.2010.154

10. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134(7):48-72. https://doi.org/10.1043/1543-2165-134.7.e48

11. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797):747-52. https://doi.org/10.1038/35021093

12. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19):10869-74. https://doi.org/10.1073/pnas.191367098

13. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8):1160-7. https://doi.org/10.1200/JCO.2008.18.1370
14. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18(2):123-33. https://doi.org/10.1634/theoncologist.2012-0397

15. Prat A, Cheang MC, Galván P, Nuñiforo P, Paré L, Adamo B, et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol 2016; 2(10):1287-94. https://doi.org/10.1001/jamaoncol.2016.0922

16. Lehmann BD, Jovanović B, ChenX, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 2016; 11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368

17. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12(5):R68. https://doi.org/10.1186/bcr2635

18. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarty AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7):2750-67. https://doi.org/10.1172/JCI45014

19. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19(19):5533-40. https://doi.org/10.1158/1078-0432.CCR-13-0799

20. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21(7):1688-98. https://doi.org/10.1158/1078-0432.CCR-14-0432

21. Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, et al. Clinical characteristics in patients with triple negative breast cancer. Int J Breast Cancer 2017; 2017:1796145. https://doi.org/10.1155/2017/1796145

22. Sadanandam A, Korlimarla A, Ragulan C, Prabhu J, Shankaranarayana H, Cheang M, et al. Indian triple-negative breast cancer – immune, molecular and clinical landscape. Ann Oncol 2017; 28(10).

23. Gogoi G, Borgohain M, Saikia P, Fazal SA. Profile of molecular subtypes of breast cancer with special reference to triple negative: A study from Northeast India. Clin Cancer Investig J 2016; 5(5):374-83.

24. Sharma M, Sharma JD, arma A, Ahmed S, Kataki AC, Saxena R, et al. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev2014; 15(11):4507-11. https://doi.org/10.7314/apjcp.2014.15.11.4507

25. Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob Oncol 2016; 2(6):412-21. https://doi.org/10.1002/jgo.005397

26. Ma KK, Chau WW, Wong CH, Wong K, Fung N, Lee AJ, et al. Triple
negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev 2012; 13(5):2109-14. https://doi.org/10.7314/apjcp.2012.13.5.2109

27. Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J. Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev 2013; 14(6):3779-84. https://doi.org/10.7314/apjcp.2013.14.6.3779

28. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27(15):2474-81. https://doi.org/10.1200/JCO.2008.19.2567

29. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379(9814):432-44. https://doi.org/10.1016/S0140-6736(11)60122-8

30. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines or diagnosis, treatment and follow-up. Ann Oncol 2015; 26(suppl 5):8-30. https://doi.org/10.1093/annonc/mdv298.

31. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33(1):13-21. https://doi.org/10.1200/JCO.2014.61.7393

32. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12. San Antonio.

33. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15(7):747-56. https://doi.org/10.1016/S1470-2045(14)70160-3

34. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33(17):1902-9. https://doi.org/10.1200/JCO.2014.57.6660

35. Zhang P, Yin Y, Mo H, Zhang B, Wang X, Li Q, et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomised trial. Lancet Oncol 2015; 16(8):934-42. https://doi.org/10.1016/S1470-2045(15)70261-1

93
breast cancer: a randomized phase 2 trial. Oncotarget 2016; 7(37):60647-56. 
https://doi.org/10.18632/oncotarget.10607
36. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70(20):7970-80. https://doi.org/10.1158/0008-5472.CAN-09-4521
37. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28(3):375-9. 
https://doi.org/10.1200/JCO.2008.20.7019
38. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26(26):4282-8. 
https://doi.org/10.1200/JCO.2008.16.6231
39. Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, et al. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer 2016; 16(1):673. https://doi.org/10.1186/s12885-016-2698-y.
40. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21):2492-502. 
https://doi.org/10.1001/jama.295.21.2492
41. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005; 294(15):1925-33. 
https://doi.org/10.1001/jama.294.15.1925
42. Anwar SL, Haryono SJ, Aryandono A, Pals G, Wahyono A, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, et al. BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat 2007; 106(2):297-304. https://doi.org/10.1007/s10549-006-9493-4
43. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60(5):1013-20.
44. Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, et al. Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. J Med Genet 2018; 55(2):97-103. 
https://doi.org/10.1136/jmedgenet-2017-104947
45. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000; 39(25):7559-69. https://doi.org/10.1021/bi0003442
46. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity
to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66(16):8109-15. 
https://doi.org/10.1158/0008-5472.CAN-06-0140

48. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2012; 8(12):571-6. 
https://doi.org/10.1016/s1471-4914(02)02434-6

49. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011; 458(1):55-64. 
https://doi.org/10.1007/s00428-010-0988-3

50. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127(3):861-9. 
https://doi.org/10.1007/s10549-011-1441-2

51. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3):205-14. 
https://doi.org/10.1056/NEJMo1101418

52. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32(34):3840-7. 
https://doi.org/10.1200/JCO.2014.55.2984

53. Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer IJ, Buxton MB, et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med 2016; 375(1):23-34. 
https://doi.org/10.1056/NEJMoa1513749

54. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377(6):523-33. 
https://doi.org/10.1056/NEJMo1706450

55. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366(1):2-16. 
https://doi.org/10.1016/j.gene.2005.10.018

56. Seshacharyulu P, Ponusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(1):15-31. 
https://doi.org/10.1517/14728222.2011.648617

57. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GH, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012; 136(2):331-45. 
https://doi.org/10.1007/s10549-012-2289-9

58. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int 2013; 2013:546318. 
https://doi.org/10.1155/2013/546318

59. Changavi AA, Shashikala A, Ramji AS. Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas. J Lab Physicians 2015; 7(2):79-83. 
https://doi.org/10.4103/0974-
60. Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L, et al. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 2012; 27(6):785-92. https://doi.org/10.14670/HH-27.785

61. Yue Y, Astvatsaturyan K, Cui X, Zhang X, Fraass B, Bose S. Stratification of prognosis of triple-negative breast cancer patients using combinatorial biomarkers. PLoS One 2006; 11(3):e0149661. https://doi.org/10.1371/journal.pone.0149661

62. Choi J, Jung WH, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol 2012; 27(11):1481-93. https://doi.org/10.14670/HH-27.1481

63. Kim A, Jang MH, Lee SJ, Bae YK. Mutations of the epidermal growth factor receptor gene in triple-negative breast cancer. J Breast Cancer 2017; 20(2):150-9. https://doi.org/10.4048/jbc.2017.20.2.150.

64. Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 2013; 71(5):1183-90. https://doi.org/10.1007/s00280-013-2112-2

65. Berndorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011; 126(2):463-70. https://doi.org/10.1007/s10549-011-1352-2

66. Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31(20):2586-92. https://doi.org/10.1200/JCO.2012.46.2408

67. Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, et al. N0436 (alliance): a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy. Clin Breast Cancer 2016; 16(1):23-30. https://doi.org/10.1016/j.clbc.2015.08.002

68. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30(21):2615-23. https://doi.org/10.1200/JCO.2010.34.5579

69. Asano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers 2017;9(1):e4. https://doi.org/10.3390/cancers9010004

70. Agrawal A, Ziołkowski P, Grzebieniak Z, Jelen M, Bobinski P, Agrawal S. Expression of androgen receptor in estrogen receptor-positive breast cancer. Appl
71. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23(2):205-12. https://doi.org/10.1038/modpathol.2009.159

72. Chottanapund S, Van Duursen MBM, Ratchaworapong K, Navasumrit P, Ruchirawat M, Van den Berg M. Androgen receptor expression in Thai breast cancer patients. Med Sci (Basel) 2016; 4(3):15. https://doi.org/10.3390/medsci4030015

73. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014; 27(3):352-60. https://doi.org/10.1038/modpathol.2013.145

74. Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients. Breast Cancer (Auckl) 2012; 6:1-8. https://doi.org/10.4137/BCBMR.S8323

75. Gucaip A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19(19):5505-12. https://doi.org/10.1158/1078-0432.CCR-12-3327

76. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 2016;27(5):812-8. https://doi.org/10.1093/annonc/mdw067

77. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol 2018; 36(9):884-90. https://doi.org/10.1017/jco.2016.71.3495

78. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11(11):3887-95.

79. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018; 18(3):153-67. https://doi.org/10.1038/nri.2017.108

80. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14(8):561-84. https://doi.org/10.1038/nrd4591

81. Ren X, Wu H, Lu J, Zhang Y, Luo Y, Xu Q, et al. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biol Ther 2018; 19(5):373-73. https://doi.org/10.1080/15384047.2018.1423919

82. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple negative breast cancer. Cancer Immunol Res 2014; 2(4):361-70.
Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study. J Clin Oncol 2016; 34(21):2460-7. https://doi.org/10.1200/JCO.2015.64.8931

84. Schmid P, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. J Clin Oncol 2017; 35(suppl):556.

85. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012; 490(7418):61-70. https://doi.org/10.1038/nature11412

86. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23(12):2965-70. https://doi.org/10.1158/1055-9965.EPI-14-0654

87. AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, et al. High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer patients. Int J Biol Sci 2017; 13(9):1172-9. https://doi.org/10.7150/ijbss.20868

88. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor-2 positive and triple-negative primary breast cancers. J Clin Oncol 2015;33(9):983-91. https://doi.org/10.1200/JCO.2014.58.1967

89. Nanda R, Liu MC, Yau C, Asare S, Hylton N, Van’t Veer L, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J Clin Oncol 2017; 35(Suppl 15):506.

90. Adams S, Loi S, Toppmeyer D, Cescon DW, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. Clin Oncol 2017; 35(suppl 15):1088.

91. Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2016; 34(suppl):1009.

92. Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27(8):1525-31. https://doi.org/10.1093/annonc/mdw203

93. Manikhas A, Kovalenko E, Manzyuk V, Bolotina LV, Zhilyaeva L, Karabina E. Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: Real life experience. J Clin Oncol 2017; 35(suppl 15):e12580.

94. Eisai Co., Ltd. Updated Analysis Of Phase Ib/Ii Study Of Eribulin And Pembrolizumab Combination Regimen In Metastatic Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium. Accessed Feb Wednesday, 2018. http://www.eisai.com/news/enews201770pdf.pdf.

95. Coradini D, Biganzoli E, Ardoino I, Ambrogi F, Boracchi P, Demicheli R, et al. p53 status identifies triple-negative breast cancer patients...
who do not respond to adjuvant chemotherapy. Breast 2015; 24(3):294-7.
https://doi.org/10.1016/j.breast.2015.01.007

96. Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. JpnJ Clin Oncol2011; 41(2):172-9.
https://doi.org/10.1093/jjco/hyq227

97. Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, et al. Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer 2015; 15(6):473-81.e3.
https://doi.org/10.1016/j.clbc.2015.04.008

98. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012; 33(11):2007-17.
https://doi.org/10.1093/carcin/bgs232

99. Synnott NC, Murray AM, O'Donovan N, Duffy MJ, Crown J. Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells. J Clin Oncol 2017; 35(suppl 15):e14098.

100. Westin SN, Nieves-Neira W, Lynam C, Salim KY, Silva AD, Ho RT, Mills GB, Coleman RL, Janku F, Matei D. Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018. Cancer Res 2018; 78(13): Abstract nr CT033.

101. Gourley C, Green J, Gabra H, Vergote I, Basu B, Brenton JD, Björklund U, Smith AM, Euler MV. PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). J Clin Oncol 2016; 5571.

102. Lü L, Mao X, Shi P, He B, Xu K, Zhang S, et al. Micro RNAs in the prognosis of triple-negative breast cancer. Medicine (Baltimore) 2017; 96(22):e7085.
https://doi.org/10.1093/md/MD.000000000007085.

103. Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol 2012; 7:31.
https://doi.org/10.1186/1746-1596-7-31

104. Chen LL, Zhang ZJ, Yi ZB, Li JJ. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Br J Cancer 2017; 117(1):78-88.
https://doi.org/10.1038/bjc.2017.150

105. Mitra S. MicroRNA therapeutics in triple negative breast cancer. Arch Pathol Clin Res 2017; 1:009-017.
https://doi.org/10.29328/journal.hjpcr.1001003

106. Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014; 9(5):e96228.
https://doi.org/10.1371/journal.pone.0096228

107. Wu J, Sun Z, Sun H, Li Y. MicroRNA 27a promotes tumorigenesis via targeting AKT in triple negative breast cancer. Mol Med Rep 2018; 17(1):562-70.
https://doi.org/10.3892/mmr.2017.7886

108. Sun X, Li Y, Zheng M, Zuo W, Zheng W. MicroRNA-223 increases the
sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1. PLoS One 2016; 11(9):e0162754. 
https://doi.org/10.1371/journal.pone.0162754

109. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 2017; 31(6):820-32.e3. 
https://doi.org/10.1016/j.ccell.2017.04.013

110. Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis 2017; 6(10):e385. 
https://doi.org/10.1038/oncsis.2017.86

111. Polivka JJr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014; 142(2):164-75. 
https://doi.org/10.1016/j.pharmthera.2013.12.004

112. Solzak JP, Atale RV, Hancock BA, Sinn AL, Pollok KE, Jones DR, et al. Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer 2017; 3:17. 
https://doi.org/10.1038/s41523-017-0016-8

113. de Lint K, Poell JB, Soueidan H, Jastrzebski K, Vidal Rodriguez J, Lieftink C, et al. Sensitizing triple-negative breast cancer to PI3K inhibition by cotargeting IGF1R. Mol Cancer Ther 2016; 15(7):1545-56. 
https://doi.org/10.1158/1535-7163.MCT-15-0865

114. Gohr K, Hamacher A, Engelke LH, Kassack MU. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer 2017; 17(1):711. 
https://doi.org/10.1186/s12885-017-3695-5

115. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase I trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol 2017; 3(4):509-15. 
https://doi.org/10.1001/jamaoncol.2016.5281

116. Tumonggor MK, Karafet TM, Hallmark B, Lansing JS, Sudoyo H, Hammer MF, et al. The Indonesian archipelago: an ancient genetic highway linking Asia and the Pacific. J Hum Genet 2013; 58(3):165-73. 
https://doi.org/10.1038/jhg.2012.154

117. Dent R, Trudeau M, Pritchard KL,Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2017; 13(15 Pt 1):4429-34. 
https://doi.org/10.1158/1078-0432.CCR-06-3045

118. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19(11):1847-52. 
https://doi.org/10.1093/annonc/mdn395

119. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 2009; 15(5):454-60. 
https://doi.org/10.1111/j.1524-4741.2009.00789.x

120. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8):1275-81. 
https://doi.org/10.1200/JCO.2007.14.4147
121. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384(9938):164-72. https://doi.org/10.1016/S0140-6736(13)62422-8

122. Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, et al. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget 2016; 7(43):69649-65. https://doi.org/10.18632/oncotarget.11935